The Cannim Story
Cannim’s story is one of purpose driven collaboration to help those suffering needlessly when medicinal cannabis can help; a passion to help Jamaica and to keep Australia at the forefront of medical advances; and the aspiration to be the Australasian leader of the global movement in the fastest growing industry worldwide.
Cannim’s genesis was the four Worton brothers in Jamaica and Australia who recognised the benefits of medicinal cannabis from personal memories that it provided pain relief in cancer (and also helped treat asthma attacks and anxiety with “ganja tea”!).
After research and meetings with people involved in cannabis cultivation, processing, hardware, cannabis testing labs, budding cannabis venture capitalists, doctors and universities in geographies ranging from Jamaica to California, Oregon and Massachusetts as well as Australia, a plan to enter the market evolved.
The plan was based on 3 issues identified:
- quality standards and product information were not widespread
- cultivation was traditionally an “art” rather than a consistent approach
- production was fragmented with unpredictable supply
Based on prior experience with raising capital and listing businesses in the USA and Australia, the bold plan initiated was to create a business with a scale that could significantly impact the global industry.
Jamaica Red Moon was incorporated in Jamaica in January 2017 with Cannim Group incorporated in Australia afterwards.
One of the first decisions was to acquire a farm of 500 acres in Jamaica.
However, with the brothers recognising their limitations, the very first decision was to identify and recruit an expert team.
This is Cannim’s main asset: a committed, diverse team with a demonstrable track record of success in their fields. The team includes world renown thought leaders and pioneers from Israel effectively transplanting Israel’s global market leadership in medicinal cannabis to Cannim’s Jamaican operations. Other expertise ranges from managing farms over 1,000s of acres, “big-pharma” and drug development; legal and M&A, regulatory compliance, logistics and security; through to capital markets and entrepreneurial acumen.
Cannabis culture runs deep in the soul of Jamaica. Not just in the popular image of Bob Marley and reggae music or even as a spiritual sacrament by Rastafarians and their association with “ganja”. Cannabis has been an integral part of traditional Jamaican remedies with an infusion of cannabis in white over-proof rum a staple component of every grandmothers’ medicine cabinet.
Less well known is that the first approved pharmaceutical drug developed from cannabis was in Jamaica in 1983 called Canasol for the treatment of Glaucoma, with Asthmasol launched for the treatment of Asthma in 1990.
Importantly, widespread use of cannabis in Jamaica means it is a beacon to researchers who want to study its effects.
Australia’s cannabis legislation was slower to develop than in Jamaica so Cannim’s priority was on securing licenses, initiating cultivation and generating revenue from Jamaica.
Cannim has now acquired an Australian farm and has applied for licenses to replicate its Jamaican operations. and to leverage the global talent and capital it has attracted. Underpinned by research, Australian operations will focus on the emerging Australian and Asian markets.
Bold visions cannot be achieved alone and Cannim attracted talent and formed alliances to cooperate internationally on systems, strains and know-how developed over combined decades of anecdotal and regulated use of medicinal cannabis.
From our strategic beach-heads in Israel, Jamaica, Australia, the UK and Europe, we are extending our relationships to the China, Asia, Africa and the Americas.
With significant offtake agreements already established, our common purpose of delivering medicinal cannabis as part of cannabis’ movement from the shadow into the light© is being achieved.
A world leading vertically integrated medicinal cannabis company that reclaims cannabis and restores health.
An expert international team building a premium vertically integrated medicinal and wellness cannabis business to supply safe and reliable products to restore health around the world.
Cannim is built on three values, safety, science and scale. We believe these are necessary to be successful in the medicinal cannabis arena. The cannabis industry is plighted with product inconsistency and unfounded claims. Through keeping these values at the foundation of everything Cannim does, we are able to ensure quality cannabis and consistency of supply for healthier outcomes.
We are dedicated to the health and well being of our clients. We grow select strains and apply state of the art standard operating procedures to ensure safe and effective premium outputs. We test throughout the course of our cultivation, extraction, processing and packaging.
We support medical translational research and collaboration in Jamaica, Australia and Europe. Clinical evidence continues to show specific cannabis strains and extract formulations deliver specific health benefits. Our team and partnerships place us at the forefront of cannabinoid research.
Our scale of cultivation and processing, partnered with our global team and alliances, ensures we provide a consistent and reliable supply of quality products that will meet burgeoning international demand.
With Cannim’s various international operations, it has established itself as a fully vertically integrated company. This ensures safety, science and scale is applied at every stage from cultivation to processing, final production and distribution. Cannim also goes a step further by using a circular integration model.
Circular integration takes vertical integration to another level. While Cannim controls every level of the value chain, it also applies scientific and anecdotal research at each stage to better refine its processes and products. This means we get feedback throughout our value chain to drive continuous improvement.
With its motivated and experienced executive team, Cannim’s gene to medi-scene© business ensures that it is not reliant on third party providers but can control and ensure quality, as well as realise economies of scale for cost and price efficiencies.
As a means of generating competitive advantage, Cannim’s licenses range from cultivation to research and development and processing, in keeping with its plans for a circular integrated modular business “from gene to medi-scene©” . This is illustrated below, centred around testing (for safety), translational research to support cannabis treatment (science) and driving for the scale necessary for reliable, consistent, medicinal quality output.
Medicinal cannabis markets are in their infancy. We have developed a detailed strategic plan to maximise the market opportunity and grow our product and brand.
Our key market segments are:
Opioid Addiction Treatment Centre
Cannabis Healthy Beverages
Significant components of our German and UK marketing plan will include:
- Corporate Communications
- Analysis and Assessment
- Stakeholder Engagement
- Education and outreach
- Strategic communication
- Tactical and budget requirements
We are taking 3 alternative routes to market, Direct, through Alliances, and through Channels. Cannim has had success in each of these approaches and is now in discussions to replicate these approaches and expedite growth.
This gives us direct access to the market. We have signed an off-take agreement with one of the 8 original licensees in Israel. The agreement specifies initial quantities with pricing at market rates.
We have signed a teaming agreement with the oldest pharmaceutical company in Jamaica to co-develop medicinal cannabis products and to be their exclusive supplier of cannabis. We will distribute through their channels to 20 countries including UK, Canada and the USA.
We have signed an off-take agreement with an emerging specialist cannabis group which has been setting up distribution channels in Europe for more than two years. They have been interacting with governments, national pharmacy chains and associations.
Since formation, a number of key milestones to progress the business have been reached.